Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability

[1]  J. Brunet,et al.  Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Giordano,et al.  From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. , 2008, Current medicinal chemistry.

[3]  B. Park,et al.  PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? , 2007, Cancer cell.

[4]  J. Mosley,et al.  Rapamycin inhibits multiple stages of c-Neu/ErbB2–induced tumor progression in a transgenic mouse model of HER2-positive breast cancer , 2007, Molecular Cancer Therapeutics.

[5]  G. Del Sal,et al.  The Prolyl Isomerase Pin1 Affects Che-1 Stability in Response to Apoptotic DNA Damage* , 2007, Journal of Biological Chemistry.

[6]  Q. Ma,et al.  Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells. , 2007, Oncology reports.

[7]  Z. Xiang,et al.  Loss of Hsp90 Association Up-Regulates Src-Dependent ErbB2 Activity , 2006, Molecular and Cellular Biology.

[8]  D. Ma,et al.  Pin1 contributes to cervical tumorigenesis by regulating cyclin D1 expression. , 2006, Oncology reports.

[9]  Etienne Waelkens,et al.  The Protein Phosphatase 2A Phosphatase Activator Is a Novel Peptidyl-Prolyl cis/trans-Isomerase* , 2006, Journal of Biological Chemistry.

[10]  Elisabeth S Yeh,et al.  The Loss of PIN1 Deregulates Cyclin E and Sensitizes Mouse Embryo Fibroblasts to Genomic Instability* , 2006, Journal of Biological Chemistry.

[11]  J. Gutkind,et al.  Regulation of the Transcriptional Activity of c-Fos by ERK , 2005, Journal of Biological Chemistry.

[12]  Akira Yamaguchi,et al.  Stable Suppression of Tumorigenicity by Pin1-Targeted RNA Interference in Prostate Cancer , 2005, Clinical Cancer Research.

[13]  K. Lu,et al.  Phosphorylation-specific prolyl isomerization: is there an underlying theme? , 2005, Nature Cell Biology.

[14]  Ming Zhou,et al.  Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.

[15]  J. Isola,et al.  Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. , 2005, Cancer research.

[16]  P. Pandolfi.  Breast cancer--loss of PTEN predicts resistance to treatment. , 2004, The New England journal of medicine.

[17]  M. Karin,et al.  Jun Turnover Is Controlled Through JNK-Dependent Phosphorylation of the E3 Ligase Itch , 2004, Science.

[18]  Priti Garg,et al.  Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis , 2004, The EMBO journal.

[19]  E. Raymond,et al.  Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Sowadski,et al.  Prevalent overexpression of prolyl isomerase Pin1 in human cancers. , 2004, The American journal of pathology.

[21]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[22]  Joseph R. Nevins,et al.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells , 2004, Nature Cell Biology.

[23]  M. Cobleigh,et al.  Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. Epstein,et al.  Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer , 2001, Molecular and Cellular Biochemistry.

[25]  D. Slamon,et al.  Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy , 2004, Breast Cancer Research and Treatment.

[26]  S. Lavoie,et al.  Multisite phosphorylation of Pin1-associated mitotic phosphoproteins revealed by monoclonal antibodies MPM-2 and CC-3 , 2004, BMC Cell Biology.

[27]  Anna Frolov,et al.  The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. , 2003, Cancer research.

[28]  Expression status of Pin1 and cyclins in oral squamous cell carcinoma: Pin1 correlates with Cyclin D1 mRNA expression and clinical significance of cyclins. , 2003, Oncology reports.

[29]  T. Uchida,et al.  Pin1 is overexpressed in oral squamous cell carcinoma and its levels correlate with cyclin D1 overexpression. , 2003, Oncology reports.

[30]  S. Volinia,et al.  The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults , 2002, Nature.

[31]  S. Murray,et al.  The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response , 2002, Nature.

[32]  L. Neckers,et al.  Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Richard J Lee,et al.  ErbB-2-induced mammary tumor growth: the role of cyclin D1 and p27Kip1. , 2002, Biochemical pharmacology.

[34]  Sam W. Lee,et al.  PIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells , 2002, Molecular and Cellular Biology.

[35]  F. Luan,et al.  Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1 , 2002, Transplantation.

[36]  J. Noel,et al.  Critical Role of WW Domain Phosphorylation in Regulating Phosphoserine Binding Activity and Pin1 Function* , 2002, The Journal of Biological Chemistry.

[37]  T. Hunter,et al.  Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  J. Blenis,et al.  Coordinate regulation of translation by the PI 3-kinase and mTOR pathways. , 2002, Advances in cancer research.

[39]  P. Frost,et al.  mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. , 2001, Endocrine-related cancer.

[40]  Tianhua Niu,et al.  Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c‐Jun towards cyclin D1 , 2001, The EMBO journal.

[41]  Y. Geng,et al.  Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.

[42]  T. Hsu,et al.  Drosophila Pin1 prolyl isomerase Dodo is a MAP kinase signal responder during oogenesis , 2001, Nature Cell Biology.

[43]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[44]  D. Slamon,et al.  Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. , 2001, Seminars in oncology.

[45]  A. Greenleaf,et al.  Juglone, an inhibitor of the peptidyl-prolyl isomerase Pin1, also directly blocks transcription. , 2001, Nucleic acids research.

[46]  J. Kurebayashi.  Biological and clinical significance of her2 overexpression in Breast Cancer , 2001, Breast cancer.

[47]  Masafumi Nakamura,et al.  Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC , 2001, Nature Cell Biology.

[48]  M. Hidalgo,et al.  The rapamycin-sensitive signal transduction pathway as a target for cancer therapy , 2000, Oncogene.

[49]  Yosef Yarden,et al.  Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.

[50]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  L. Neckers,et al.  Polyubiquitination and Proteasomal Degradation of the p185c-erbB-2 Receptor Protein-tyrosine Kinase Induced by Geldanamycin* , 1996, The Journal of Biological Chemistry.

[53]  T. Hunter,et al.  A human peptidyl–prolyl isomerase essential for regulation of mitosis , 1996, Nature.

[54]  L. Presta,et al.  Humanization of an anti-p185HER2 antibody for human cancer therapy. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[55]  M. Hung,et al.  Multiple cis- and trans-acting elements involved in regulation of the neu gene , 1990, Molecular and cellular biology.

[56]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.